Anti-HMGCR Myopathy
Open Access
- 21 February 2018
- journal article
- review article
- Published by IOS Press in Journal of Neuromuscular Diseases
- Vol. 5 (1), 11-20
- https://doi.org/10.3233/jnd-170282
Abstract
Anti-HMGCR myopathy was first recognized and characterized in patients with a history of statin exposure and immune-mediated necrotizing myopathy. After the discovery of anti-HMGCR autoantibodies, several international groups identified and characterKeywords
This publication has 59 references indexed in Scilit:
- Increased frequency of DRB1*11:01 in anti–hydroxymethylglutaryl‐coenzyme A reductase–associated autoimmune myopathyArthritis Care & Research, 2012
- Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effectsArthritis Care & Research, 2011
- Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyArthritis & Rheumatism, 2010
- A novel autoantibody recognizing 200‐kd and 100‐kd proteins is associated with an immune‐mediated necrotizing myopathyArthritis & Rheumatism, 2010
- Immune‐mediated necrotizing myopathy associated with statinsMuscle & Nerve, 2009
- Progressive myopathy with up-regulation of MHC-I associated with statin therapyNeuromuscular Disorders, 2007
- Dermatomyositis‐like syndrome and HMG‐CoA reductase inhibitor (statin) intakeMuscle & Nerve, 2004
- 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The NetherlandsNeuromuscular Disorders, 2004
- Lovastatin-associated dermatomyositisPublished by Oxford University Press (OUP) ,1996
- Simvastatin-associated DermatomyositisRheumatology, 1994